Biktarvy
CDC Updates Nonoccupational Post-Exposure Prophylaxis HIV Recommendations
The CDC has issued updated recommendations for antiretroviral post-exposure prophylaxis (PEP) for nonoccupational ...
MAY 29, 2025
Study Finds 1 INSTI Combo Fares Better With Weight Gain
How do you pick which drug to prescribe for your patients with HIV?
MARCH 26, 2025
Good Results With Biktarvy in HIV–HBV Coinfection
At CROI 2025, Dr. Anchalee Avihingsanon and her colleagues reported Week 48 outcomes from the open-label extension ...
MARCH 25, 2025
Biktarvy’s Benefits Extend in Older Adults With HIV
Five-year follow-up data from the triple combination HIV therapy bictegravir-emtricitabine-tenofavir alafenamide ...
NOVEMBER 26, 2024
FDA Expands Indication for Biktarvy to for Resistant HIV
The FDA expanded the indication for bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead) to ...
FEBRUARY 29, 2024
Biktarvy Shows Durable Viral Suppression After 5 Years
Five-year cumulative data from two trials of Biktarvy demonstrated high rates of viral suppression that were ...
AUGUST 2, 2022
Counterfeit HIV Meds Found in the U.S.
Gilead Sciences warned that tampered and counterfeit versions of its HIV medications, Biktarvy and Descovy, are in ...
AUGUST 10, 2021
New ART Suppresses HIV in Treatment-Experienced Adults
High rates of virologic suppression were seen in treatment-experienced adults who switched to BIC/FTC/TAF, ...
MARCH 25, 2019
Switching HIV Regimen Found Safe
Switching to the newly approved Biktarvy in virologically suppressed adults maintained viral suppression with fewer ...
MARCH 7, 2018
ViiV Files Suit Against Gilead Over HIV Drug Patents
ViiV claims bictegravir infringes on its patent covering dolutegravir and many other compounds that include ...
FEBRUARY 8, 2018
FDA Approves Biktarvy Triple Therapy for HIV Infection
The FDA approved Gilead's Biktarvy, a once-daily, single-tablet regimen for the treatment of HIV-1 infection.
FEBRUARY 8, 2018
